Globus Medical price target raised to $60 from $55 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on Globus Medical to $60 from $55 and keeps a Neutral rating on the shares. The firm notes Globus Medical announced Q1 results, which solidly beat on the top and bottom lines. The company raised full year guidance, albeit by less than the beat though management noted clear conservatism with this move, Piper adds.